| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 12.59M | 9.04M | 14.02M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 12.59M | 9.04M | 14.02M | -631.00K | -755.00K | -755.00K |
| EBITDA | -187.92M | -151.35M | -28.00M | -36.27M | -23.95M | -17.04M |
| Net Income | -212.39M | -292.96M | -106.81M | -37.51M | -24.71M | -17.84M |
Balance Sheet | ||||||
| Total Assets | 296.29M | 240.24M | 148.54M | 24.05M | 57.92M | 44.52M |
| Cash, Cash Equivalents and Short-Term Investments | 268.04M | 217.30M | 138.14M | 20.32M | 49.23M | 39.77M |
| Total Debt | 4.14M | 4.83M | 1.65M | 291.00K | 317.00K | 613.00K |
| Total Liabilities | 27.02M | 59.08M | 28.66M | 7.39M | 9.74M | 3.18M |
| Stockholders Equity | 269.27M | 181.16M | 119.88M | 16.65M | 48.19M | 41.34M |
Cash Flow | ||||||
| Free Cash Flow | -186.17M | -117.97M | -8.40M | -28.94M | -18.30M | -12.72M |
| Operating Cash Flow | -178.68M | -110.79M | -7.57M | -28.69M | -18.23M | -12.13M |
| Investing Cash Flow | -25.23M | -85.06M | -30.48M | -248.00K | -79.00K | -586.00K |
| Financing Cash Flow | 182.56M | 240.53M | 116.41M | 32.00K | 27.77M | 49.94M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | $1.30B | ― | -51.86% | ― | -37.09% | 58.96% | |
| ― | $1.37B | ― | -81.20% | ― | 16.74% | 59.89% | |
| ― | $1.24B | ― | -17.34% | ― | 83.36% | 22.27% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | $791.14M | -9.66 | -31.09% | ― | 11877.28% | 63.14% | |
| ― | $833.90M | ― | -76.09% | ― | -42.84% | -17.32% | |
| ― | $1.45B | ― | -109.12% | ― | ― | 7.58% |
Immunome, Inc. is a biotechnology company specializing in the development of targeted cancer therapies, with a focus on first-in-class and best-in-class treatments in the oncology sector. The company is advancing a diverse portfolio of therapeutics, including antibody-drug conjugate therapies.